Treatment of venous thromboembolism with new oral anticoagulants according to patient risk

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 2, 2015, Pages 160-165

  Schulman, Sam ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

bleeding; factor Xa inhibitors; heparin; thrombin inhibitors; venous thromboembolism; vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; GASTROINTESTINAL HEMORRHAGE; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LONG TERM CARE; LUNG EMBOLISM; OUTPATIENT CARE; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; PATIENT MONITORING; PATIENT RISK; POINT OF CARE TESTING; PRIORITY JOURNAL; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; ORAL DRUG ADMINISTRATION; PERSONALIZED MEDICINE; RISK FACTOR;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; INDIVIDUALIZED MEDICINE; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84923921654     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1544157     Document Type: Article

References (37)

1. Hirsh J., Bauer K. A., Donati M. B., Gould M., Samama M. M., Weitz J. I.; American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 (6, Suppl): 141S 159S
2. Alhenc-Gelas M., Jestin-Le Guernic C., Vitoux J. F., Kher A., Aiach M., Fiessinger J. N.; Fragmin-Study Group. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Thromb Haemost: 1994; 71 6 698 702
3. Koopman M. M., Prandoni P., Piovella F., et al. The Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med: 1996; 334 11 682 687
4. Levine M., Gent M., Hirsh J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med: 1996; 334 11 677 681
5. Aujesky D., Roy P. M., Verschuren F., et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet: 2011; 378 9785 41 48
6. Moser K. M., Fedullo P. F., LitteJohn J. K., Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA: 1994; 271 3 223 225
7. Nielsen H. K., Husted S. E., Krusell L. R., Fasting H., Charles P., Hansen H. H. Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. J Intern Med: 1994; 235 5 457 461
8. Schulman S., Lindmarker P., Holmström M., et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost: 2006; 4 4 734 742
9. Lecumberri R., Alfonso A., Jiménez D., et al. RIETE investigators. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemost: 2013; 110 4 834 843
10. Aujesky D., Obrosky D. S., Stone R. A., et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med: 2005; 172 8 1041 1046
11. Aujesky D., Perrier A., Roy P. M., et al. Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism. J Intern Med: 2007; 261 6 597 604
12. Jiménez D., Aujesky D., Moores L., et al. RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med: 2010; 170 15 1383 1389
13. Zondag W., Vingerhoets L. M., Durian M. F., et al. Hestia Study Investigators. Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function. J Thromb Haemost: 2013; 11 4 686 692
14. Agnelli G., Buller H. R., Cohen A., et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med: 2013; 369 9 799 808
15. Bauersachs R., Berkowitz S. D., Brenner B., et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med: 2010; 363 26 2499 2510
16. Büller H. R., Prins M. H., Lensin A. W., et al. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med: 2012; 366 14 1287 1297
17. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res: 2008; 122 6 743 752
18. Kearon C., Akl E. A., Comerota A. J., et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 (2, Suppl): e419S e494S
19. Lim W., Dentali F., Eikelboom J. W., Crowther M. A. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med: 2006; 144 9 673 684
20. Schulman S., Beyth R. J., Kearon C., Levine M. N.; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 (6, Suppl): 257S 298S
21. Casserly L. F., Dember L. M. Thrombosis in end-stage renal disease. Semin Dial: 2003; 16 3 245 256
22. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron: 1976; 16 1 31 41
23. Kearon C., Ginsberg J. S., Julian J. A., et al. Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA: 2006; 296 8 935 942
24. Lee A. Y., Levine M. N., Baker R. I., et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med: 2003; 349 2 146 153
25. van Es N., Coppens M., Schulman S., Middeldorp S., Büller H. R. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood: 2014; 124 12 1968 1975
26. Heit J. A., O'Fallon W. M., Petterson T. M., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med: 2002; 162 11 1245 1248
27. Rahme E., Feugère G., Sirois C., Weicker S., Ramos E. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study. Thromb Res: 2013; 131 3 210 217
28. Schulman S., Eriksson H., Goldhaber S. Z., et al. Influence of renal function on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-Cover and RE-Cover II. Blood: 2013; 122 21 212
29. Schulman S., Eriksson H., Goldhaber S. Z., et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-Cover and RE-Cover II. Blood: 2013; 122 21 2375
30. Agnelli G., Buller H. R., Cohen A., et al. PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med: 2013; 368 8 699 708
31. Huang J., Cao Y., Liao C., Wu L., Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost: 2011; 105 2 245 253
32. Granger C. B., Alexander J. H., McMurray J. J., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
33. Connolly S. J., Eikelboom J., Joyner C., et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med: 2011; 364 9 806 817
34. Zhang D., Frost C. E., He K., et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos: 2013; 41 4 906 915
35. Rodger M. A., Kahn S. R., Wells P. S., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ: 2008; 179 5 417 426
36. Schulman S., Kearon C., Kakkar A. K., et al. RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med: 2013; 368 8 709 718
37. Connolly S. J., Wallentin L., Ezekowitz M. D., et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation: 2013; 128 3 237 243